{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:35:42Z","timestamp":1768638942043,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.vaccine.2018.10.095","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T09:06:32Z","timestamp":1542618392000},"page":"8039-8046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada"],"prefix":"10.1016","volume":"36","author":[{"given":"Gaston","family":"De Serres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-No\u00eblle","family":"Billard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Claude","family":"Gari\u00e9py","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eveline","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique","family":"Landry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Boulianne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Gagn\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Gilca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3592-6324","authenticated-orcid":false,"given":"Genevi\u00e8ve","family":"Deceuninck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manale","family":"Ouakki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danuta M","family":"Skowronski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.10.095_b0005","unstructured":"National Advisory Comittee on Immunization. Advice for the use of the Multicomponent Meningococcal Serogroup B (4CMenB) Vaccine. Public Health Agency of Canada, Ottawa, 2014, [On line]. http:\/\/www.phac-aspc.gc.ca\/naci-ccni\/mening-4cmenb-eng.php."},{"key":"10.1016\/j.vaccine.2018.10.095_b0010","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62(RR-2)","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"9","key":"10.1016\/j.vaccine.2018.10.095_b0015","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/cix154","article-title":"Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada","volume":"64","author":"De Wals","year":"2017","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"issue":"9816","key":"10.1016\/j.vaccine.2018.10.095_b0020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2018.10.095_b0025","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.10.095_b0030","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.095_b0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vaccine Immunol mars"},{"issue":"10","key":"10.1016\/j.vaccine.2018.10.095_b0040","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2018.10.095_b0045","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"CMAJ"},{"issue":"6","key":"10.1016\/j.vaccine.2018.10.095_b0050","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/hv.7.6.15482","article-title":"The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccin"},{"issue":"9698","key":"10.1016\/j.vaccine.2018.10.095_b0055","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(09)61208-3","article-title":"Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials","volume":"374","author":"Prymula","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.10.095_b0060","unstructured":"GlaxoSmithKline. BEXSERO\u00ae Multicomponent Meningococcal B Vaccine (recombinant, adsorbed). [On line]: http:\/\/ca.gsk.com\/media\/1212390\/bexsero.pdf"},{"issue":"7","key":"10.1016\/j.vaccine.2018.10.095_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038563","article-title":"Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccine","volume":"7","author":"De Serres","year":"2012","journal-title":"PLoS ONE"},{"issue":"29","key":"10.1016\/j.vaccine.2018.10.095_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES2015.20.29.21189","article-title":"Successful methodology for large-scale surveillance of severe events following influenza vaccination in Canada, 2011 and 2012","volume":"20","author":"Bettinger","year":"2015","journal-title":"Euro Surveill"},{"issue":"7","key":"10.1016\/j.vaccine.2018.10.095_b0075","doi-asserted-by":"crossref","first-page":"E215","DOI":"10.1503\/cmaj.141200","article-title":"Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months","volume":"187","author":"McQuaid","year":"2015","journal-title":"CMAJ"},{"issue":"34","key":"10.1016\/j.vaccine.2018.10.095_b0080","first-page":"4046","article-title":"Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting","volume":"34","author":"Langley","year":"2016","journal-title":"A Can Immun Res Network study. Vacc"},{"issue":"7","key":"10.1016\/j.vaccine.2018.10.095_b0085","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.4161\/hv.28666","article-title":"A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)","volume":"10","author":"Prymula","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2018.10.095_b0090","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.4161\/hv.29218","article-title":"A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II)","volume":"10","author":"Esposito","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.095_b0095","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/INF.0000000000001056","article-title":"Persistence of bactericidal antibodies after infant serogroup B meningococcal immunization and booster dose response at 12, 18 or 24 months of age","volume":"35","author":"Snape","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.10.095_b0100","unstructured":"Esposito S, Vesikari T, Kimura A. Tolerability of a three-dose schedule of an investigational, multicomponent, meningococcal serogroup B vaccine and routine infant vaccines in a lot consistency trial. Poster session presented at: 17th International Pathogenic Neisseria Conference (IPNC). 2010, September 11-16: Banff, AB, Canada."},{"key":"10.1016\/j.vaccine.2018.10.095_b0105","unstructured":"Martin NG, Snape MD, Robinson H. Reactogenicity and safety of investigational serogroup B meningococcal vaccines given at 40 months of age to primed and vaccine naive children. Poster session presented at: XVIIIth International Pathogenic Neisseria Conference (IPNC). 2012, September 9-14: Wurzburg, Germany."},{"key":"10.1016\/j.vaccine.2018.10.095_b0110","unstructured":"Vesikari T, Prymula R, Liese J, Kollaritsch H, Bona G, Kimura A, et al. Booster dose at 12 months of an investigational meningococcal serogroup B vaccine (4CMenB) in healthy toddlers previously primed at 2, 4, 6 months. in: 29th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). 2011, June 7-11: The Hague, Netherlands."},{"issue":"10","key":"10.1016\/j.vaccine.2018.10.095_b0115","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/archdischild-2016-311020","article-title":"Emergency department attendance following 4-component meningococcal B vaccination in infants","volume":"102","author":"Kapur","year":"2017","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2018.10.095_b0120","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/archdischild-2017-312941","article-title":"An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study","volume":"102","author":"Nainani","year":"2017","journal-title":"Arch Dis Child"},{"issue":"10","key":"10.1016\/j.vaccine.2018.10.095_b0125","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/archdischild-2017-313079","article-title":"Risk of hospitalisation with fever following MenB vaccination: self-controlled case series analysis","volume":"102","author":"Murdoch","year":"2017","journal-title":"Arch Dis Child."},{"issue":"6","key":"10.1016\/j.vaccine.2018.10.095_b0130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2352-4642(18)30103-2","article-title":"Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study","volume":"2","author":"Bryan","year":"2018","journal-title":"Lancet Child Adolesc Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18314920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18314920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:29:20Z","timestamp":1759400960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18314920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":26,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0264410X18314920"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.095","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}